EGFR and non-small cell lung carcinoma: Recently, some studies have validated 2,3‐disubstituted quinazolinones as promising scaffolds for EGFR inhibition and NSCLC management (compounds F and G)7,24, the addition of a lipophilic group at the 2‐position improving overall activity.23